News : Diamyd Medical

View:
 

Found press releases

 

Diamyd Medical's Phase III study published in the New England Journal of Medicin...

2/2/2012 2:30 AM EST  -   Diamyd Medical
An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association’s 71st Scientific Sessions in San Diego, California, USA, on June 28, 2011.
The title of the published article is “GAD65...

Quarterly Report I 11/12

1/25/2012 2:30 AM EST  -   Diamyd Medical
Quarterly Report Diamyd Medical AB (publ), fiscal year 2011/2012
(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)
Reporting period September 1, 2011 – November 30, 2011
-    Group total net sales amounted to MSEK 0.1 (144.5)
-    Profit before tax amounted to MSEK -7.4 (98.3)
-    Earnings per share after dilution were SEK -0.26 (3.32)
-    The Group’s liquid assets amounted to MSEK 414 (478) as...

Prevention study with Diamyd´s diabetes vaccine fully recruited

1/9/2012 2:30 AM EST  -   Diamyd Medical
A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical’s diabetes vaccine Diamyd®. The study is thus fully recruited. The purpose of the study is to evaluate whether preventive treatment with Diamyd® can delay or halt the progression of the disease so that the children do not develop...

Annual Report 10/11

12/8/2011 12:42 PM EST  -   Diamyd Medical
Q1

• Results from Phase I study in cancer pain shows promising safety data and relief of chronic pain

Q2

• Recruitment for US Phase III study in type 1 diabetes is completed

• Phase II study in cancer pain is started

• University of Florida Research Foundation initiates court case against Diamyd Medical

Q3

• Results of a Phase I clinical study in cancer pain is published in the medical journal Annals of...

Bulletin from Annual General Meeting: Diamyd Medical towards new goals

12/7/2011 1:18 PM EST  -   Diamyd Medical
At Diamyd Medical’s Annual General Meeting on December 7, Peter Zerhouni, President and CEO, commented that the past year had been eventful and turbulent, but that the Company now stands well-equipped to continue its efforts to develop innovative pharmaceuticals for diseases for which there are currently no effective treatment options.
The event that dominated the latter part of Diamyd Medical’s fiscal year was...

University of Florida Research Foundation and Diamyd Medical settle lawsuit

11/17/2011 2:30 AM EST  -   Diamyd Medical
University of Florida Research Foundation, Incorporated (“UFRF”), and Diamyd Medical AB today jointly announced that they have settled the breach of contract litigation that UFRF filed in the United States Federal District Court in Florida against Diamyd Medical in January 2011.
The dispute related to an exclusive license agreement between UFRF and Diamyd Medical, and to a sublicense of the rights under the...

Information about Summons to the Annual General Meeting of Diamyd Medical AB

11/7/2011 1:31 PM EST  -   Diamyd Medical
The follwing summons to the Annual General Meeting will be available at Diamyd Medical's website www.diamyd.com from Wednesday November 9, 2011.
Summons to the Annual General Meeting of Diamyd Medical AB

The shareholders of Diamyd Medical AB (publ) are hereby summoned to the Annual General Meeting on Wednesday December 7, 2011 at 3.00 p.m. in Stora Hörsalen, Garnisonen, at Karlavägen 100 in Stockholm,...

Financial Statement 10/11

10/13/2011 2:30 AM EST  -   Diamyd Medical
Year End Report, Stockholm, October 13, 2011
September 1, 2010 – August 31, 2011

Fourth quarter report for Diamyd Medical AB (publ.), fiscal year 2010/2011
(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)
Fourth quarter, June 1, 2011 – August 31, 2011

· Group net sales for the fourth quarter were MSEK 2.2 (110.2)
· Loss before tax for the fourth quarter was MSEK -26.5 (75.0)
· Earnings per...

Diamyd awarded three million dollar grant and expands the NTTDS portfolio

9/12/2011 2:30 AM EST  -   Diamyd Medical
Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company’s patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy. The grant allows Diamyd to expand the NTDDS technology to also target neuropathy, in addition to the Company’s development portfolio for the treatment of...

Diamyd puts focus on pain projects and reduces costs

8/17/2011 2:30 AM EST  -   Diamyd Medical
Diamyd Medical AB is concentrating its resources on the Company’s drug candidates for the treatment of pain and diseases of the nervous system. The termination of the Phase III program with the diabetes therapy Diamyd® means significantly lower costs for the Company which creates strategic leeway.
The primary development focus of Diamyd Medical is shifted from the diabetes therapy Diamyd® to the Company’s...